ABSTRACT
INTRODUCTION
Morgana is a protein containing two CHORD (cysteine and histidine rich) domains able to coordinate Zn ++ ions and a C-terminal CS (after CHORD-containing proteins and Sgt1) domain [1] , homologous to the small chaperones α-crystallin and p23 ( Figure 1 ) [2] . CHORD domains are phylogenetically conserved from plants to mammals. The first CHORD containing protein identified was the plant protein RAR1, involved in disease resistance signaling [1] . In metazoan and fungi CHORD containing proteins (Chps) acquired the CS domain, with the exception of yeast, that does not possess Chps [1] . While not vertebrates hold a single Chp coding gene, in vertebrates two genes are present, coding for Morgana and melusin [3, 4] . Mammalian Chps share the 63% homology in the amino acid sequence and a similar domain structure. Melusin expression is restricted to skeletal muscle and myocardium [3, 5] , where it is involved in signal transduction leading to compensatory hypertrophy in response to increased workload [6] [7] [8] [9] . Instead, Morgana is ubiquitously expressed and it is involved in the control of centrosome duplication and tumorigenesis [4, 10] .
MORGANA IS A CHAPERONE PROTEIN

CHORD containing proteins, RAR1 as well as
Morgana and melusin, have been described to bind to HSP90 [11] [12] [13] [14] [15] [16] [17] [18] . HSP90 is one of the best studied molecular chaperones in eukaryotes, accounting for the 2% of the total cytosolic protein content, acting as a dynamic dimer encompassing different molecular conformation shifts during its ATPase cycle. It consists of a N-terminal ATPase domain, a middle domain and a C-terminal dimerization domain. HSP90 interacts with two different classes of proteins: co-chaperones, able to assist and coordinate the HSP90 cycle and more than 200 substrate proteins, also known as clients, depending on HSP90 for their stabilization and activation. A number of co-chaperone proteins have been identified and described to associate dynamically with HSP90 during its chaperone cycle, among them SGT1, PP5, p23, prolylisomerase, Hop, Cdc37, melusin and Morgana [19] . Specific co-chaperones can inhibit or stimulate HSP90 ATPase activity, stabilize particular conformations or recruit other components of the chaperone machinery or specific subset of client proteins [19] . Many HSP90 clients are signaling proteins and transcription factors often involved in oncogenesis and tumor progression. Given that HSP90 inhibition leads to client protein degradation, HSP90 inhibitors are in clinical trials as anti-cancer treatment [20] . Morgana binds to HSP90 in its ADP bound conformation [17] , suggesting it might play a role in the last phase of HSP90 cycle, eventually regulating client protein release. www.impactjournals.com/oncotarget Morgana, as other HSP90 co-chaperones [21] , displays an HSP90 independent molecular chaperone activity in suppressing the aggregation of denatured proteins [15] . Different stress stimuli provoke unfolded proteins accumulation leading to cellular damage and death. Chaperone proteins, by inducing protein refolding, directing denatured proteins to degradation and inhibiting unfolded protein aggregation, are of crucial importance in limiting cellular damage and enhancing cell survival. Accordingly, Morgana overexpression protects cells from apoptosis induced by different stress stimuli, like heat shock and hydrogen peroxide [15] . Notably, in vivo experiments indicate that Morgana is upregulated, together with HSP70, in response to transient brain ischemia in gerbil hippocampus [15] . [14] . Nucleophosmin (NPM) is an ubiquitously expressed multifunctional protein, involved in a wide range of cellular processes like DNA repair, chromatin remodeling, ribosome biogenesis and centrosome duplication. NPM is often overexpressed in human solid tumors, it is involved in chromosome translocation driving hematologic neoplasms and it is the most frequently mutated gene in acute myeloid leukemia [30] . In S phase, NPM associates with and activates ROCK II, inducing centrosome duplication [31, 32] . In morgana +/-cells a higher amount of NPM binds to ROCK II, causing its hyperactivity and leading to centrosome overduplication [14] . Given that nucleophosmin does not bind to ROCK I [31], the precise mechanism by which Morgana inhibits this kinase needs to be clarified.
MORGANA IN SIGNAL TRANSDUCTION AND TUMORIGENESIS
Besides 
The importance of Morgana dosage Too low
Drosophila homozygous mutants for Morgana gene (mora) die as third instar larvae due to strong defects in cell proliferation. In particular, larval neuroblasts show strong impairment in chromosome condensation and the presence of supernumerary centrosomes leading to apoptosis or genomic instability. These phenotypes are fully rescued by a human Morgana gene, indicating a conserved role of Morgana between mammals and Drosophila. Moreover, Morgana null mice die early during embryogenesis and Morgana null embryonic stem cells undergo apoptosis when blastocysts are cultured in vitro. Morgana heterozygous mice are viable, however primary cells obtained from these mice display centrosome amplification and genomic instability, in accordance with the phenotype of Drosophila homozygous mutants [14] . ROCK hyperactivation caused by Morgana haploinsufficiency, is responsible for this phenotype and the use of ROCK inhibitors can rescue centrosome overduplication and consequently genomic instability in morgana +/-primary cells [14] . This Morgana function seems to have ancient phylogenetic roots, in fact, Morgana homolog CHPA has been described to be essential for the maintenance of genome stability in Aspergillus nidulans in diploid phase [37] .
The anti-oncogenic role of Morgana was firstly disclosed by analyzing morgana +/-mouse embryonic fibroblasts (MEFs) that display a higher proliferation rate and oncogenic features [14] . Moreover, Morgana heterozygous mice are more susceptible to chemical induction of lung tumors and with age they develop spontaneously a lethal and transplantable myeloproliferative disease resembling human chronic myeloid leukemia (CML) [38] . In humans, CML is a myeloproliferative disorder caused, in the vast majority of cases, by the translocation t(9;22)(q34;q11) that results in the formation of the so called Philadelphia chromosome (Ph). This cytogenetic abnormality causes the fusion between BCR and ABL genes and leads to the expression of a constitutively active Bcr/Abl kinase. Imatinib, a tyrosine kinase inhibitor (TKI) able to target Bcr/ Abl, is the first-line therapy in CML treatment, leading to a complete hematologic remission in the majority of patients [39] (Figure 2 ). However, 5% of CML patients do not present the Philadelphia chromosome and lack BCR/ABL oncogene, being affected by "atypical" CML (aCML) [40] . Of note, this disease is characterized by aneuploid karyotypes [40] [41] [42] and non recurrent cytogenetic abnormalities in the bone marrow. Morgana haploinsufficiency is able per se to drive the pathology, given that the BCR/ABL translocation does not occur in kinase Bcr/Abl that leads to the hyperactivation of several signaling pathways, including PI3K, ROCK, MAPK and JAK-STAT signaling pathways [39] , enhancing proliferation and survival (on the left). CML cells are addicted to Bcr/Abl signaling and Bcr/Abl inhibition using imatinib, induces apoptosis in these cells (on the right).
mice [43] . When we analyzed bone marrow biopsies from 5 patients affected by aCML, we found low/indetectable Morgana expression levels and high ROCK activity in all cases. In this context, reduced Morgana levels could be the causal event in inducing the pathology. The absence of specific and common targetable mutations makes aCML patients ineligible for target therapies. To date, the only therapeutic option for these patients is the treatment with conventional cytoreductive drugs with a median overall survival of 12.4 months [44] . morgana +/-diseased bone marrow cells are addicted to ROCK signaling and ROCK inhibitors induce apoptosis in these cells but not in wild-type controls (Figure 3 ) [44] . Thus, ROCK can be exploited as an innovative therapeutic target in Morgana low aCML. The fact that the ROCK inhibitor fasudil is safely used in Japan since 1995 for the treatment of cerebral vasospasm, makes this possibility even more attractive.
Not only low Morgana expression levels can be the driving cause of human aCML, but our work highlighted that Morgana downregulation cooperates with the BCR/ ABL oncogene in the 16% of CML Ph positive (Ph+) patients. Bcr/Abl is able to activate ROCK per se, and Bcr/Abl expressing cells are addicted to both Bcr/Abl and ROCK signaling [29, 45] . Since Morgana acts as a ROCK inhibitor, low Morgana levels in Bcr/Abl cells further increase ROCK activity and sustain ROCK activation also when Bcr/Abl kinase activity is inhibited by imatinib treatment, impairing apoptotic response to imatinib (Figure 4 left) . Even if the majority of the Ph+ CML patients show a good response to imatinib at three months of treatment, a portion of patients exhibits a suboptimal response that has been found to be predictive of worse overall survival [46] . Our follow-up analysis indicated that low Morgana patients display a worse response during the first 24 months of imatinib treatment [38] . In this context, low Morgana levels can be used as a prognostic marker to predict a suboptimal response to imatinib treatment and to direct therapeutic intervention towards more potent, second-generation TKI like dasatinib and nilotinib. The fact that combined treatment with imatinib and ROCK inhibitors restores the apoptotic response in bone marrow cells from Morgana underexpressing patients [38] (Figure  4 right) provides the rationale for a potential use of ROCK inhibitors to enhance the response to TKI. Indeed, ROCK hyperactivation has been recently identified as a frequent signaling alteration in acute and chronic myeloid leukemia and ROCK inhibitors have been proposed as new antileukemic drugs [29, 47] . In this context, also considering the functional relationship between Morgana and NPM, it would be of interest to evaluate Morgana expression levels in acute myeloid leukemia and its role, in cooperation with oncogenes, in activating ROCK. activity which sustains survival of these cells establishing a mechanism of oncogene addiction (on the left). In fact, when ROCK is pharmacologically inhibited using fasudil, these cells can no longer survive and undergo apoptosis (on the right). www.impactjournals.com/oncotarget
Too high
Data from lung and breast tumor tissue arrays demonstrate that besides expressing low Morgana levels, a minority of cancer samples displays Morgana protein overexpression [14] . Elevated Morgana levels in breast cancer correlate with higher tumor grade, mitosis number and lymph node involvement [10], all prognostic markers of metastatic progression [48] . Morgana overexpression is found in 16% of breast cancers without being restricted to a particular subtype.
At the cellular level, Morgana overexpression transforms NIH3T3 mouse fibroblasts and increases MCF7 breast cancer cells oncogenic properties. In particular, high Morgana levels enhance the ability of cells to withstand diverse apoptotic stimuli such as serum withdrawal, anoikis and treatment with chemotherapic drugs. Resistance to apoptosis depends on Morgana ability to inhibit ROCK I kinase activity. In particular, ROCK I can phosphorylate the oncosuppressor PTEN on serine 229 and threonine 321 [49] , thereby stabilizing the protein.
Accordingly, Morgana overexpression in breast cancer cells and fibroblasts induces decreased ROCK activity, PTEN destabilization and higher P-AKT levels, leading to apoptosis resistance ( Figure 5 ). This is confirmed by the fact that downregulation of Morgana in aggressive breast cancer cells causes sensitization to docetaxel and epirubicin, two drugs used for neo-adjuvant chemotherapy. Neo-adjuvant chemotherapy is often used in breast cancer patients to improve outcomes, reduce risk of recurrence, increase tumor resectability and overall survival. However, neo-adjuvant chemotherapy treatment does also carry high risks of toxicity and is ineffective in a relevant number of patients [50] . In this context, Morgana level can be exploited as a predictive marker to direct patients toward treatment or surgery. Of note, Morgana is more frequently overexpressed in triple negative breast cancers (TNBCs) (36%) than in other breast cancer subtypes (16%) [10, 51] . TNBCs are characterized by high aggressiveness, higher rates of relapse, unresponsiveness to treatment and shorter overall survival in the metastatic setting [52] . TNBCs lack the expression of estrogen receptor (ER), progesterone receptor (PR) and the amplification of HER2 [53] , for this reason, TNBC patients are not eligible for targeted therapies and adjuvant chemotherapy is the mainstay of systemic medical treatment. The fact that high Morgana levels induce AKT hyperactivation, suggests that PI3K or AKT inhibitors, already in clinical trial [54] , may have a therapeutic effect in Morgana overexpressing cancers. Besides breast cancers, recent studies indicate that Morgana overexpression may play a role in the recurrence, resistance and metastatization of other cancer types (Table 1) , suggesting Morgana as a general biomarker of resistance able to direct personalized therapy.
CONCLUSIONS
Deletions and amplifications in cancer cells are known to alter oncosuppressor and oncogene expression levels and lead to cancer onset and progression. Even small variations in the expression of key regulatory genes impact very relevantly on tumorigenesis [55] . However, the fact that the same gene product can cause cancer either if overexpressed (three times compared to the normal level) or underexpressed (half of the normal level), is still puzzling. This apparent paradox can be explained by keeping in mind that most proteins play multiple roles in cells. Abnormal expression of a multifunctional protein involved in both oncogenic and oncosuppressive signaling pathways can eventually lead to the prevalence of one function over the other, in a context-dependent manner. Indeed, elevated ROCK expression and activity has been detected in different types of hematopoietic [29, 47, 56, 57] and solid tumors [22, 58] and ROCK I and ROCK II activating somatic mutations have been found in cancers [59] [60] [61] [62] . On the other hand, some studies report alteration in the expression of ROCK inhibitors and activators, like RhoE [63, 64] and RhoA [65] [66] [67] , suggesting a role for ROCK inactivation in tumorigenesis.
Morgana is thus only one example of an increasingly growing class of proteins, acting both as proto-oncogenes and oncosuppressors (Figure 6 ), depending on their expression levels and the specific cellular context. NPM [68, 69] , Wilms' tumor 1 (WT1) [70] , MDM2 [71] , Notch [72] , Met, NF-KB, β-catenin [73] , SRPK1 [74] , among others, have also been described to play opposite role in tumorigenesis. In conclusion, the definition of oncogene or oncosuppressor cannot be attributed to a particular gene product, but to its specific behavior in a defined cellular context.
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